ANAC Insider Trading Activity and SEC Form 4 Filings
ANAC insider trading summary
No open-market insider purchases or sales of Anacor Pharmaceuticals, Inc. (ANAC) have been reported on SEC Form 4 in the past 12 months.
Latest ANAC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 1, 2016 | Graeme Bell | Executive VP and CFO | Sell | $75K (751 @ $99.28) |
| May 23, 2016 | Keith R Leonard | Director | Sell | $897K (9,000 @ $99.70) |
| May 16, 2016 | Anders D Hove | Director | Sell | $7.2M (72,385 @ $98.93) |
| May 16, 2016 | Anders D Hove | Director | Sell | $19.9M (199,865 @ $99.41) |
| May 16, 2016 | Anders D Hove | Director | Sell | $8.2M (81,631 @ $100.60) |
| Apr 29, 2016 | Ryan T Sullivan | EVP and General Counsel | Sell | $207K (3,125 @ $66.33) |
| Apr 8, 2016 | Anders D Hove | Director | Sell | $271K (3,868 @ $70.05) |
| Apr 8, 2016 | Anders D Hove | Director | Sell | $29K (400 @ $71.40) |
| Apr 7, 2016 | Anders D Hove | Director | Sell | $167K (2,272 @ $73.29) |
| Apr 7, 2016 | Anders D Hove | Director | Sell | $7.1M (99,981 @ $71.44) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.